CLL Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASCO 2022: Study Sheds Light on Richter’s Syndrome in Patients With CLL
ASCO 2022: How Informed Are Patients With CLL in North America and the European Union?
ASCO 2022: Novel BCL2 Inhibitor Under Study in Treatment of Resistant CLL
ASCO 2022: Racial/Ethnic Identity and Overall Survival for Patients With CLL
ASCO 2022: Extended Follow-up With Obinutuzumab, Ibrutinib, and Venetoclax in CLL
ASCO 2022: 3-Year Follow-up on Fixed-Duration Ibrutinib/Venetoclax in First-Line Setting in CLL
MicroRNA Modulation of the TGF-β Pathway in CLL: Novel Molecular Connection?
Focal Adhesion Kinase: Potential Therapeutic Target in CLL?
Lisocabtagene Maraleucel CAR T-Cell Therapy in Patients With CLL
Response to Shingles Vaccine Among Patients Treated With BTK Inhibitors for CLL
How Effective Is COVID-19 Vaccination in Patients With CLL?
Addition of Novel BTK Inhibitor Pirtobrutinib to Combination Therapy May Improve Resistant CLL
AACR 2022: Fixed-Duration Regimen of Ibrutinib/Venetoclax for CLL With High-Risk Features
AACR 2022: ATR Inhibitor Alone or With BTK Inhibitor in High-Risk Resistant CLL
AACR 2022: MEK Inhibition as Potential Alternative Therapy for Patients With CLL
AACR 2022: Is Loss of the AID Enzyme Linked to Progression of CLL?
AACR 2022: PI3Kδ Inhibitor Zandelisib Under Study in CLL
Newly Developed Health-Related Quality-of-Life Questionnaire for CLL Treatment Decision-Making
Adding EP4 Receptor Agonists to CD20 Antigen Therapy in B-Cell Malignancies
Prognostic Value of Epigenetic Classification System in Patients With CLL
Is the CLL Comorbidity Index a Prognostic Tool in Research and Clinical Practice?
CD105 Expression: A Potential Risk Marker in CLL?
Can Olive Phenols Benefit Patients With CLL?
Chromosomal Microarray Analysis: Prognostic for Patients With Richter Transformation?
FDA Brief: Supplemental New Drug Application Accepted for Zanubrutinib in CLL
COVID-19 Vaccination Effectiveness in Patients With CLL: Focus on Humoral Response
Exploring the Combination of PD-1 and CDK9 Inhibitors in Hematologic Cancers
Does Interleukin 9 Play a Role in the Pathogenesis of CLL?
Novel BTK Inhibitor Alone or in Combination With Ublituximab and Umbralisib in CLL
Ibrutinib-Based Initial Therapy for Younger, Fit Patients With CLL
Initial Results of French Trial of Ibrutinib Plus Venetoclax in Intermediate-Risk CLL
Time-Limited Venetoclax-Based Combination Therapies for CLL
In Memoriam: Remembering Hematologist Steve E. Coutre, MD
Updated Phase I/II BRUIN Study of Next-Generation BTK Inhibitor Pirtobrutinib in CLL
SEQUOIA Update on Zanubrutinib Versus Bendamustine Plus Rituximab in CLL
Preclinical Findings With Novel CDK9 Inhibitor in CLL


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.